Citadel Advisors’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $44.3M | Sell |
2,115,491
-210,634
| -9% | -$4.74M | 0.01% | 1472 |
|
|
2025
Q4 | $53.5M | Buy |
2,326,125
+1,995,172
| +603% | +$65.6M | 0.01% | 1349 |
|
|
2025
Q3 | $9.96M | Buy |
330,953
+293,326
| +780% | +$8.8M | ﹤0.01% | 3279 |
|
|
2025
Q2 | $1.37M | Sell |
37,627
-218,922
| -85% | -$7.89M | ﹤0.01% | 6450 |
|
|
2025
Q1 | $9.29M | Sell |
256,549
-29,630
| -10% | -$1.23M | ﹤0.01% | 2960 |
|
|
2024
Q4 | $12M | Buy |
286,179
+238,226
| +497% | +$11.8M | ﹤0.01% | 2744 |
|
|
2024
Q3 | $2.66M | Sell |
47,953
-125,995
| -72% | -$6.42M | ﹤0.01% | 4997 |
|
|
2024
Q2 | $7.15M | Sell |
173,948
-119,357
| -41% | -$5.1M | ﹤0.01% | 3236 |
|
|
2024
Q1 | $13.7M | Buy |
293,305
+93,251
| +47% | +$4.4M | ﹤0.01% | 2516 |
|
|
2023
Q4 | $9.57M | Buy |
200,054
+198,653
| +14,179% | +$7.7M | ﹤0.01% | 2909 |
|
|
2023
Q3 | $49.9K | Sell |
1,401
-275,282
| -99% | -$10.9M | ﹤0.01% | 11764 |
|
|
2023
Q2 | $12.8M | Sell |
276,683
-281,133
| -50% | -$13M | ﹤0.01% | 2371 |
|
|
2023
Q1 | $22.4M | Buy |
557,816
+337,840
| +154% | +$14.5M | ﹤0.01% | 1811 |
|
|
2022
Q4 | $10.2M | Buy |
219,976
+36,970
| +20% | +$1.45M | ﹤0.01% | 2814 |
|
|
2022
Q3 | $7.58M | Sell |
183,006
-834,297
| -82% | -$42.9M | ﹤0.01% | 3174 |
|
|
2022
Q2 | $60.7M | Sell |
1,017,303
-297,729
| -23% | -$18.3M | 0.02% | 875 |
|
|
2022
Q1 | $95.5M | Sell |
1,315,032
-128,415
| -9% | -$8.93M | 0.02% | 682 |
|
|
2021
Q4 | $121M | Sell |
1,443,447
-39,703
| -3% | -$3.23M | 0.02% | 560 |
|
|
2021
Q3 | $134M | Sell |
1,483,150
-373,329
| -20% | -$33.7M | 0.03% | 516 |
|
|
2021
Q2 | $177M | Buy |
1,856,479
+911,966
| +97% | +$95M | 0.04% | 365 |
|
|
2021
Q1 | $108M | Buy |
944,513
+438,003
| +86% | +$59.6M | 0.03% | 555 |
|
|
2020
Q4 | $70.1M | Buy |
506,510
+57,123
| +13% | +$6.78M | 0.02% | 743 |
|
|
2020
Q3 | $36.9M | Sell |
449,387
-207,833
| -32% | -$17.2M | 0.01% | 1060 |
|
|
2020
Q2 | $51.4M | Sell |
657,220
-969,888
| -60% | -$64.2M | 0.02% | 783 |
|
|
2020
Q1 | $72.3M | Buy |
1,627,108
+128,466
| +9% | +$6.67M | 0.03% | 475 |
|
|
2019
Q4 | $64M | Buy |
1,498,642
+1,059,896
| +242% | +$43.7M | 0.03% | 635 |
|
|
2019
Q3 | $18.8M | Sell |
438,746
-45,320
| -9% | -$2.46M | 0.01% | 1529 |
|
|
2019
Q2 | $30.7M | Sell |
484,066
-490,006
| -50% | -$31.2M | 0.01% | 1050 |
|
|
2019
Q1 | $67.6M | Buy |
974,072
+963,599
| +9,201% | +$55.1M | 0.03% | 548 |
|
|
2018
Q4 | $456K | Sell |
10,473
-182,348
| -95% | -$9.97M | ﹤0.01% | 6537 |
|
|
2018
Q3 | $14.7M | Sell |
192,821
-274,751
| -59% | -$22.3M | 0.01% | 1685 |
|
|
2018
Q2 | $35.9M | Sell |
467,572
-17,007
| -4% | -$1.1M | 0.02% | 889 |
|
|
2018
Q1 | $24.7M | Buy |
484,579
+190,219
| +65% | +$9.58M | 0.01% | 969 |
|
|
2017
Q4 | $13.7M | Buy |
294,360
+269,271
| +1,073% | +$13.2M | 0.01% | 1427 |
|
|
2017
Q3 | $1.34M | Buy |
25,089
+20,746
| +478% | +$1.23M | ﹤0.01% | 3918 |
|
|
2017
Q2 | $270K | Sell |
4,343
-6,238
| -59% | -$376K | ﹤0.01% | 6074 |
|
|
2017
Q1 | $717K | Buy |
10,581
+7,074
| +202% | +$539K | ﹤0.01% | 4482 |
|
|
2016
Q4 | $247K | Sell |
3,507
-977
| -22% | -$69.3K | ﹤0.01% | 5958 |
|
|
2016
Q3 | $318K | Buy |
+4,484
| New | +$286K | ﹤0.01% | 5583 |
|
|
2016
Q2 | – | Sell |
-380,035
| Closed | -$24.6M | – | 7291 |
|
|
2016
Q1 | $24.1M | Buy |
380,035
+296,319
| +354% | +$19.4M | 0.03% | 647 |
|
|
2015
Q4 | $9.39M | Buy |
83,716
+26,574
| +47% | +$2.66M | 0.01% | 1328 |
|
|
2015
Q3 | $5.5M | Sell |
57,142
-125,041
| -69% | -$14.3M | 0.01% | 1844 |
|
|
2015
Q2 | $18.7M | Sell |
182,183
-439,290
| -71% | -$34.1M | 0.02% | 1043 |
|
|
2015
Q1 | $38.6M | Buy |
621,473
+248,618
| +67% | +$13.8M | 0.04% | 606 |
|
|
2014
Q4 | $16.4M | Buy |
372,855
+164,112
| +79% | +$7.52M | 0.02% | 1078 |
|
|
2014
Q3 | $11.8M | Buy |
208,743
+2,168
| +1% | +$109K | 0.01% | 1251 |
|
|
2014
Q2 | $9.27M | Buy |
206,575
+154,023
| +293% | +$6.34M | 0.01% | 1320 |
|
|
2014
Q1 | $2.57M | Buy |
+52,552
| New | +$2.71M | ﹤0.01% | 2399 |
|
Other funds holding RARE
VPM
VCM
RI
SI
BG
Citadel Advisors's RARE Position: Q1 2026 in Review
Citadel Advisors reduced its Ultragenyx Pharmaceutical (RARE) stake by 9.1% in Q1 2026, selling an estimated $4.74M and leaving 2,115,491 shares worth $44.3M. The position accounts for 0.01% of the portfolio, ranked #1472.
Citadel Advisors first reported a position in RARE in Q1 2014 and has held it in 48 quarters since. The position peaked at $177M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.
- Citadel Advisors held 2,115,491 shares of Ultragenyx Pharmaceutical worth $44.3M as of Q1 2026.
- Citadel Advisors sold 210,634 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $4.74M.
- Ultragenyx Pharmaceutical made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1472 holding.
- Citadel Advisors first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 48 quarters since.
- Citadel Advisors's Ultragenyx Pharmaceutical position peaked at $177M in Q2 2021.
- 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.